Skip to main content

CRL Charles River Laboratories International, Inc.

Healthcare

359.41 Close 10/30
Since 2024-12-02 +78.6%
Open
372.99
High
374.56
Low
351.98
Prev close
376.10
Volume
1.5M
Amplitude
6.00%
P/B
6.0
Revenue YoY (TTM)
-0.7%
52W 146.20 379.63

Is Charles River Laboratories International, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Growth: Good, Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E -74.11 N/A
Price / book 6.04 86th percentile Expensive
Free-cash-flow yield (%) 2.16 55th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral Operating margin, TTM is Good, but ROE, TTM is Average.
ROE, TTM (%) -8.4 32th percentile Average
Operating margin, TTM (%) 12.35 60th percentile Good
FCF margin, TTM (%) 9.27 60th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Good Diluted EPS growth, TTM YoY is Top, but Revenue growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) -0.74 34th percentile Average
Diluted EPS growth, TTM YoY (%) 264.66 91th percentile Top
Momentum Strong All 2 indicators are Top.
60-day return (%) 35.37 96th percentile Top
240-day return (%) 114.18 97th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 395,890,147 96th percentile Top
60-day annualized volatility (%) 40.27 46th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Charles River Laboratories International, Inc. (CRL) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Charles River Laboratories International, Inc. to every stock like it

AI finds several complementary traits of Charles River Laboratories International, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. (CRL) peers and tracking

Watchlist

This page refreshes daily after the close. Add Charles River Laboratories International, Inc. to your watchlist to track signal changes on your next visit.

Charles River Laboratories International, Inc. (CRL) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

26 historical occurrences (since 2017-02-14)

Average forward return after 52-week adjusted-price high

20-day: Win 60%, Sample 25, Median +1.69%, Excess +0.69%, Beat mkt rate 56%

60-day: Win 56%, Sample 25, Median +2.59%, Excess +1.34%, Beat mkt rate 52%

120-day: Win 66.7%, Sample 24, Median +7.88%, Excess +4.38%, Beat mkt rate 54.2%

120 days after: historical avg +11.33%

20-day +0.76%
60-day +3.28%
120-day +11.33%
20-day
60-day
120-day
Win
60%
56%
66.7%
Sample
25
25
24
Median
+1.69%
+2.59%
+7.88%
Excess
+0.69%
+1.34%
+4.38%
Beat mkt rate
56%
52%
54.2%

Over 24 occurrences, 120-day forward avg gained 11.33%, beat the market by 4.38 pts; win rate 66.7%.

Top-quintile 6-month momentum

Active · now 98.64%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
16 historical occurrences (since 2017-05-08)

Average forward return after Top-quintile 6-month momentum

20-day: Win 75%, Sample 16, Median +4.03%, Excess +2.72%, Beat mkt rate 50%

60-day: Win 68.8%, Sample 16, Median +8.97%, Excess +6.72%, Beat mkt rate 68.8%

120-day: Win 66.7%, Sample 15, Median +5.45%, Excess +7.01%, Beat mkt rate 53.3%

120 days after: historical avg +13.94%

20-day +2.96%
60-day +8.45%
120-day +13.94%
20-day
60-day
120-day
Win
75%
68.8%
66.7%
Sample
16
16
15
Median
+4.03%
+8.97%
+5.45%
Excess
+2.72%
+6.72%
+7.01%
Beat mkt rate
50%
68.8%
53.3%

Over 15 occurrences, 120-day forward avg gained 13.94%, beat the market by 7.01 pts; win rate 66.7%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

34 times historically; 60-day forward avg +5.79%, win rate 53.1%, beating the market by +2.01 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.